---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-044093"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2026-04-16T23:59:59+00:00"
generated_at: "2026-05-15T05:49:08.819663+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acurx raises ~$2.5M in registered direct offering plus up to $4.6M from warrants

## Summary
- Priced 825,085 shares (or pre-funded warrants) at $3.03/share for ~$2.5M gross proceeds.
- Concurrent private placement of 1,650,170 Series H warrants at $2.78/share, exercisable for 24 months.
- Potential additional gross proceeds of ~$4.6M if short-term warrants fully exercised on cash basis.
- Proceeds to be used for working capital and general corporate purposes.
- H.C. Wainwright & Co. acted as exclusive placement agent; fees 6.0% of gross proceeds.

## SEC filing metadata
- accession: 0001104659-26-044093
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2026-04-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465926044093/0001104659-26-044093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465926044093/tm2611957d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-044093
- JSON: https://secwatch.observer/filing/0001104659-26-044093.json
- Plain text: https://secwatch.observer/filing/0001104659-26-044093.txt

## Source-grounded claims
- claim_id: 314114a99e855d1216a84880c8c142fb8c04631a
  claim: Acurx Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the investors named therein (the "Investors") valued at aggregate gross proceeds of approximately $2.5 million (effective 2026-04-15).
  evidence_excerpt: On April 15, 2026, Acurx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Registered Offering”) (i) 816,068 shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a purchase price of $3.03 per share and (ii) pre-funded common stock purchase warrants (the “Pre-Funded Warrants”) to purchase up to 9,017 shares of Common Stock (the “Pre-Funded Warrant Shares”) at a purchase price of $3.029 per share for aggregate gross proceeds of approximately $2.5 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736243/000110465926044093/0001104659-26-044093-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.